Abstract
Due to an increased need for new antimalarial chemotherapies that show potency against Plasmodium falciparum, researchers are targeting new processes within the parasite in an effort to circumvent or delay the onset of drug resistance. One such promising area for antimalarial drug development has been the parasite mitochondrial electron transport chain (ETC). Efforts have been focused on targeting key processes along the parasite ETC specifically the dihydroorotate dehydrogenase (DHOD) enzyme, the cytochrome bc 1 enzyme and the NADH type II oxidoreductase (PfNDH2) pathway. This review summarizes the most recent efforts in antimalarial drug development reported in the literature and describes the evolution of these compounds.
| Original language | English |
|---|---|
| Pages (from-to) | 50-65 |
| Number of pages | 16 |
| Journal | Parasitology |
| Volume | 141 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 1 Jan 2014 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Antimalarial
- dihydroorotate dehydrogenase
- drug development
- mitochondrial
- PfNADH II
- structure-activity relationships
Fingerprint
Dive into the research topics of 'Novel inhibitors of the Plasmodium falciparum electron transport chain'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver